Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT)

EINSTEIN-Jr Cerebral Venous Thrombosis trial investigators, Philip Connor, Mayte Sánchez van Kammen, Anthonie W.A. Lensing, Elizabeth Chalmers, Krisztián Kállay, Kerry Hege, Paolo Simioni, Tina Biss, Fanny Bajolle, Damien Bonnet, Sebastian Grunt, Riten Kumar, Olga Lvova, Rukhmi Bhat, An van Damme, Joseph Palumbo, Amparo Santamaria, Paola Saracco, Jeanette PayneSusan Baird, Kamar Godder, Veerle Labarque, Christoph Male, Ida Martinelli, Michelle Morales Soto, Jayashree Motwani, Sanjay Shah, Helene L. Hooimeijer, Martin H. Prins, Dagmar Kubitza, William T. Smith, Scott D. Berkowitz, Akos F. Pap, Madhurima Majumder, Paul Monagle, Jonathan M. Coutinho

Research output: Contribution to journalArticlepeer-review

Abstract

Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard anticoagulants in the predefined subgroup of children with cerebral venous thrombosis (CVT) who participated in the EINSTEIN-Jr trial. Children with CVT were randomized (2:1), after initial heparinization, to treatment with rivaroxaban or standard anticoagulants (continued on heparin or switched to vitamin K antagonist). The main treatment period was 3 months. The primary efficacy outcome, symptomatic recurrent venous thromboembolism (VTE), and principal safety outcome, major or clinically relevant nonmajor bleeding,were centrally evaluated by blinded investigators. Sinus recanalization on repeat brain imaging was a secondary outcome. Statistical analyses were exploratory. In total, 114 children with confirmed CVT were randomized. All children completed the follow-up. None of the 73 rivaroxaban recipients and 1 (2.4%; CVT) of the 41 standard anticoagulant recipients had symptomatic, recurrent VTE after 3 months (absolute difference, 2.4%; 95% confidence interval [CI], 22.6% to 13.5%). Clinically relevant bleeding occurred in 5 (6.8%; all nonmajor and noncerebral) rivaroxaban recipients and in 1 (2.5%; major [subdural] bleeding) standard anticoagulant recipient (absolute difference, 4.4%; 95% CI, 26.7% to 13.4%). Complete or partial sinus recanalization occurred in 18 (25%) and 39 (53%) rivaroxaban recipients and in 6 (15%) and 24 (59%) standard anticoagulant recipients, respectively. In summary, in this substudy of a randomized trial with a limited sample size, children with CVT treated with rivaroxaban or standard anticoagulation had a low risk of recurrent VTE and clinically relevant bleeding. This trial was registered at clinicaltrials.gov as #NCT02234843.

Original languageEnglish
Pages (from-to)6250-6258
Number of pages9
JournalBlood advances
Volume4
Issue number24
DOIs
Publication statusPublished - Dec 22 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT)'. Together they form a unique fingerprint.

Cite this